Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,791 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.
Bornhäuser M, Schliemann C, Schetelig J, Röllig C, Kramer M, Glass B, Platzbecker U, Burchert A, Hänel M, Müller LP, Klein S, Bug G, Beelen D, Rösler W, Schäfer-Eckart K, Schmid C, Jost E, Lenz G, Tischer J, Spiekermann K, Pfirrmann M, Serve H, Stölzel F, Alakel N, Middeke JM, Thiede C, Ehninger G, Berdel WE, Stelljes M. Bornhäuser M, et al. Among authors: schmid c. JAMA Oncol. 2023 Apr 1;9(4):519-526. doi: 10.1001/jamaoncol.2022.7605. JAMA Oncol. 2023. PMID: 36757706 Free PMC article. Clinical Trial.
DLI: where are we know?
Kolb HJ, Schmid C, Buhmann R, Tischer J, Ledderose G. Kolb HJ, et al. Among authors: schmid c. Hematology. 2005;10 Suppl 1:115-6. doi: 10.1080/10245330512331390122. Hematology. 2005. PMID: 16188651 No abstract available.
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.
Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, Harsdorf SV, Scheid C, Holtick U, Greinix H, Keil F, Schneider B, Sandherr M, Bug G, Tischer J, Ledderose G, Hallek M, Hiddemann W, Kolb HJ. Schmid C, et al. Blood. 2006 Aug 1;108(3):1092-9. doi: 10.1182/blood-2005-10-4165. Epub 2006 Mar 21. Blood. 2006. PMID: 16551971 Free article. Clinical Trial.
Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.
Schmid C, Labopin M, Nagler A, Bornhäuser M, Finke J, Fassas A, Volin L, Gürman G, Maertens J, Bordigoni P, Holler E, Ehninger G, Polge E, Gorin NC, Kolb HJ, Rocha V; EBMT Acute Leukemia Working Party. Schmid C, et al. J Clin Oncol. 2007 Nov 1;25(31):4938-45. doi: 10.1200/JCO.2007.11.6053. Epub 2007 Oct 1. J Clin Oncol. 2007. PMID: 17909197
Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group.
Schetelig J, Bornhäuser M, Schmid C, Hertenstein B, Schwerdtfeger R, Martin H, Stelljes M, Hegenbart U, Schäfer-Eckart K, Füssel M, Wiedemann B, Thiede C, Kienast J, Baurmann H, Ganser A, Kolb HJ, Ehninger G. Schetelig J, et al. Among authors: schmid c. J Clin Oncol. 2008 Nov 10;26(32):5183-91. doi: 10.1200/JCO.2007.15.5184. Epub 2008 Sep 2. J Clin Oncol. 2008. PMID: 18768435
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.
Braess J, Spiekermann K, Staib P, Grüneisen A, Wörmann B, Ludwig WD, Serve H, Reichle A, Peceny R, Oruzio D, Schmid C, Schiel X, Hentrich M, Sauerland C, Unterhalt M, Fiegl M, Kern W, Buske C, Bohlander S, Heinecke A, Baurmann H, Beelen DW, Berdel WE, Büchner T, Hiddemann W. Braess J, et al. Among authors: schmid c. Blood. 2009 Apr 23;113(17):3903-10. doi: 10.1182/blood-2008-07-162842. Epub 2009 Jan 8. Blood. 2009. PMID: 19131552 Free article. Clinical Trial.
The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
Grabrucker C, Liepert A, Dreyig J, Kremser A, Kroell T, Freudenreich M, Schmid C, Schweiger C, Tischer J, Kolb HJ, Schmetzer H. Grabrucker C, et al. Among authors: schmid c. J Immunother. 2010 Jun;33(5):523-37. doi: 10.1097/CJI.0b013e3181d87ffd. J Immunother. 2010. PMID: 20463595
1,791 results